Vancomycin is the most frequently used antibiotic, accounting for up to 35% of hospitalized
patients with infection, because of its optimal bactericidal effectiveness and relatively low …

Vancomycin is a recommended therapy in multiple national guidelines. Despite the common
use, there is a poor understanding of the mechanistic drivers and potential modifiers of …

Background This study analyzed the relationship between vancomycin area under the
concentration-time curve (AUC) and acute kidney injury (AKI) reported across recent studies …

Objectives: Critically ill patients routinely receive vancomycin as empiric antibiotic therapy. A
continuous infusion administration strategy may be superior to intermittent infusion by …

Drug-induced nephrotoxicity is responsible for 20% to 60% of cases of acute kidney injury in
hospitalized patients and is associated with increased morbidity and mortality in both …

Clinical studies have reported additive nephrotoxicity associated with the combination of
vancomycin (VAN) and piperacillin-tazobactam (TZP). This study assessed differences in …

Objectives Nephrotoxicity represents a major complication of vancomycin administration,
leading to high rates of morbidity and treatment failure. The aim of this meta-analysis was to …

Background Vancomycin and piperacillin/tazobactam are reported in clinical studies to
increase acute kidney injury (AKI). However, no clinical study has demonstrated synergistic …

Antimicrobial resistance is a major global health challenge. As few new efficacious
antibiotics will become available in the near future, peptide antibiotics continue to be major …

Nephrotoxicity is the major limiting factor for the clinical use of vancomycin (VCM) for
treatment of serious infections caused by multiresistant Gram-positive bacteria. This study …